Table 1.
Baseline Characteristics Comparing the Placebo Group Versus the Anacetrapib Group
| Placebo (n=289) | Anacetrapib (n=285) | P Value* | |
|---|---|---|---|
| Age, median (IQR), y | 63.1 (56.9–69.6) | 62.1 (55.2–68.1) | 0.24 |
| Women | 132 (46) | 99 (35) | 0.008 |
| White race | 223 (77) | 226 (79) | 0.55 |
| BMI, median (IQR), kg/m2 | 29.6 (27.0–33.4) | 29.4 (26.3–33.2) | 0.56 |
| DM | 188 (65) | 171 (60) | 0.23 |
| Atorvastatin | 97 (33.6) | 101 (35.4) | 0.007† |
| Simvastatin | 132 (45.7) | 95 (33.3) | |
| Rosuvastatin | 49 (17.0) | 62 (21.8) | |
| Pravastatin | 4 (1.4) | 13 (4.6) | |
| Lovastatin | 6 (2.1) | 13 (4.6) |
Values are presented as number (percentage) unless otherwise indicated. BMI indicates body mass index; DM, diabetes mellitus; and IQR, interquartile range.
a
P values are obtained using Wilcoxon rank sum test assuming nonparametric distributions for continuous variables and chi‐square test for categorical variables.
b
The P value for statins is shown as an overall P value.